Global Clinical Whole Exome Sequencing (WES) Market Growth (Status and Outlook) 2025-2031

Report ID: 3034992 | Published Date: Dec 2025 | No. of Page: 148 | Base Year: 2024 | Rating: 4.9 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%)

Impact of U.S Tarrifs Analyzed 2025

The global Clinical Whole Exome Sequencing (WES) market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.

Clinical Whole Exome Sequencing (WES) is a comprehensive genetic test that identifies changes in a patient's DNA that cause or are related to their medical problems. By focusing on the entire protein-coding region of the genome (the exome), it provides the coverage needed to diagnose patients quickly and reliably.

Key Features

United States market for Clinical Whole Exome Sequencing (WES) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Clinical Whole Exome Sequencing (WES) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Clinical Whole Exome Sequencing (WES) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Segmentation by Type

  • Array-Based Exome Enrichment
  • Enrichment of the Exome in Solution using Biotinylated Probes

Segmentation by Application

  • Rare Genetic Disease
  • Genetic Testing Unsuccessful
  • Others

Market by Region

  • Americas
    • United States
    • Canada
    • Mexico
    • Brazil
  • APAC
    • China
    • Japan
    • Korea
    • Southeast Asia
    • India
    • Australia
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
  • Middle East & Africa
    • Egypt
    • South Africa
    • Israel
    • Turkey
    • GCC Countries

Company's Coverage

  • CentoXome
  • Mayo Clinic Laboratories
  • Baylor Genetics
  • Blueprint Genetics
  • GeneDx
  • CD Genomics
  • Illumina
  • Thermo Fisher
  • Labassure
  • Yale Medicine
  • Genosalut
  • Caris Life Sciences
  • InterGenetics
  • Genomics and Pathology Services (GPS)
  • 3billion
  • Broad Genomic
  • Roche
  • Novogene
  • BGI Genomics
  • Shanghai Jingzhou Genomics
  • Shihe Gene Biotechnology
  • JUNO Genomics

Key Questions Addressed in this Report

What are the trends affecting the market?

What is the market size and growth forecast?
Frequently Asked Questions
Clinical Whole Exome Sequencing (WES) report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Clinical Whole Exome Sequencing (WES) report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Clinical Whole Exome Sequencing (WES) report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports